



Commonwealth of Massachusetts  
**MassHealth Drug Utilization Review Program**  
 P.O. Box 2586, Worcester, MA 01613-2586  
**Fax:** (877) 208-7428 **Phone:** (800) 745-7318

## Benzodiazepines and Other Antianxiety Agents Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about benzodiazepines or other antianxiety agents and the **Pediatric Behavioral Health Medication Initiative**, including PA requirements, a complete list of all behavioral health medications, and preferred products, can be found within the MassHealth Drug List at [www.mass.gov/druglist](http://www.mass.gov/druglist). The related PA form is available at: **Pediatric Behavioral Health Medication Initiative PA Request Form**.

### Member information

Last name \_\_\_\_\_ First name \_\_\_\_\_ MI \_\_\_\_\_  
 MassHealth member ID # \_\_\_\_\_ Date of birth \_\_\_\_\_  
 Gender (Check one.)  F  M Member's place of residence  home  nursing facility

### Medication information

**Medication requested** (check one or all that apply.)

- |                                                                                      |                                                                     |
|--------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| <input type="checkbox"/> alprazolam extended-release (ER) >2 units/day               | <input type="checkbox"/> flurazepam >1 unit/day                     |
| <input type="checkbox"/> alprazolam orally disintegrating tablet (ODT)               | <input type="checkbox"/> Loreev XR (lorazepam extended-release)     |
| <input type="checkbox"/> amitriptyline/chlordiazepoxide                              | <input type="checkbox"/> meprobamate                                |
| <input type="checkbox"/> Byfavo (remimazolam)^                                       | <input type="checkbox"/> oxazepam                                   |
| <input type="checkbox"/> clonazepam ODT 0.125 mg, 0.25 mg, 0.5 mg, 1 mg >3 units/day | <input type="checkbox"/> temazepam 7.5 mg, 15 mg, 30 mg >1 unit/day |
| <input type="checkbox"/> clonazepam ODT 2 mg >2 units/day                            | <input type="checkbox"/> temazepam 22.5 mg                          |
| <input type="checkbox"/> clorazepate                                                 | <input type="checkbox"/> triazolam >1 unit/day                      |
| <input type="checkbox"/> estazolam >1 unit/day                                       | <input type="checkbox"/> Other* _____                               |

*\*If request is for a non-preferred brand name or generic product, please attach supporting documentation (e.g., copies of medical records and/or office notes regarding adverse reaction or inadequate response to the preferred product).*

*^This drug is available through the health care professional who administers the drug. MassHealth does not pay for this drug to be dispensed through a retail pharmacy.*

**Dose, frequency, and duration of medication requested** \_\_\_\_\_ **Quantity requested per month** \_\_\_\_\_  
**Indication(s)** \_\_\_\_\_

Is this member a referral candidate for care coordination?  Yes  No

If yes, MassHealth will offer this member care coordination services. Please describe which additional behavioral health services would be beneficial.

**Section I. Concomitant Opioid and Benzodiazepine Polypharmacy. Please complete information for medications requested and clinical rationale for polypharmacy with opioids and benzodiazepines [one or more benzodiazepine(s), excluding clobazam, nasal and rectal diazepam, nasal midazolam, and injectable formulations, and one or more opioid(s) for ≥ 60 days within a 90-day period].**

Please document the indication for the agents requested.

1. Benzodiazepine

Name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

Name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

Name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

2. Opioid

Name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

Name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

Name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

Please document clinical rationale for concomitant use of opioids and benzodiazepines for this member.

Please describe the ongoing treatment plan for continued use.

For the diagnosis of a seizure disorder, is the member currently receiving a non-benzodiazepine anticonvulsant?

Yes. Drug name \_\_\_\_\_ Dates \_\_\_\_\_ Outcome \_\_\_\_\_

No. Please explain why not. \_\_\_\_\_

For the diagnosis of a sleep disorder, has the member had trials with three non-benzodiazepine sleep medications?

Yes. Drug name \_\_\_\_\_ Dates \_\_\_\_\_ Outcome \_\_\_\_\_

Drug name \_\_\_\_\_ Dates \_\_\_\_\_ Outcome \_\_\_\_\_

Drug name \_\_\_\_\_ Dates \_\_\_\_\_ Outcome \_\_\_\_\_

No. Please explain why not. \_\_\_\_\_

For the diagnosis of a psychiatric disorder (e.g., generalized anxiety disorder, panic disorder, post-traumatic stress disorder, etc.), has the member had trials with three antidepressants?

Yes. Drug name \_\_\_\_\_ Dates \_\_\_\_\_ Outcome \_\_\_\_\_

Drug name \_\_\_\_\_ Dates \_\_\_\_\_ Outcome \_\_\_\_\_

Drug name \_\_\_\_\_ Dates \_\_\_\_\_ Outcome \_\_\_\_\_

No. Please explain why not. \_\_\_\_\_

For the diagnosis of a musculoskeletal disorder, has the member had trials with three skeletal muscle relaxants?

Yes. Drug name \_\_\_\_\_ Dates \_\_\_\_\_ Outcome \_\_\_\_\_

Drug name \_\_\_\_\_ Dates \_\_\_\_\_ Outcome \_\_\_\_\_

Drug name \_\_\_\_\_ Dates \_\_\_\_\_ Outcome \_\_\_\_\_

No. Please explain why not. \_\_\_\_\_

Has consideration been given for possible taper of benzodiazepine or opioid?

Yes. Please describe plan for taper and plan to reevaluate in the future. \_\_\_\_\_

No. Please describe why taper is not possible at this time and plan to reevaluate in the future.

Has the member been hospitalized for a psychiatric condition (non-overdose related) within the past three months?

- Yes. Please document dates of hospitalization within the past three months. \_\_\_\_\_  
 No

On the current regimen, is the member considered to be a risk of harm to self or others?

- Yes. Please provide details. \_\_\_\_\_  
 No

Has the member been offered and/or given a prescription for naloxone treatment?

- Yes  No. Please provide details. \_\_\_\_\_

*\*Attach a letter with additional information regarding medication trials as applicable.*

---

**Section II. Benzodiazepine Polypharmacy for members  $\geq$  18 years of age. Please complete information for medications requested and clinical rationale for polypharmacy with benzodiazepines (two or more benzodiazepines, excluding clobazam, nasal and rectal diazepam, nasal midazolam, and injectable formulations for  $\geq$  60 days within a 90-day period).**

Please document complete treatment plan for the agents requested from the same medication class.

1. Benzodiazepine name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
2. Benzodiazepine name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
3. Benzodiazepine name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

Please document clinical rationale for polypharmacy within the same medication class for this member (include prior therapy trials, severity of symptoms, etc.)

\_\_\_\_\_

Has consideration been given for consolidation to a single benzodiazepine agent?

- Yes. Please describe plan for cross-titration or taper. \_\_\_\_\_  
 No

Please describe why dose consolidation is not possible at this time and plan to reevaluate in the future.

\_\_\_\_\_

Has the member been hospitalized for a psychiatric condition within the past three months?

- Yes. Please document dates of hospitalization within the past three months. \_\_\_\_\_  
 No

On the current regimen, is the member considered to be a risk of harm to self or others?

- Yes. Please provide details. \_\_\_\_\_  
 No

---

**Section III. Please complete for requests for alprazolam ODT.**

Please describe the medical necessity for use of the requested dosage formulation. Include prior trials of agents and describe dose consolidation as appropriate.

\_\_\_\_\_

---

**Section IV. Please complete for requests for  $>$  1 unit/day of estazolam, flurazepam, temazepam (7.5 mg, 15 mg, and 30 mg), and triazolam,  $>$  2 units/day of alprazolam ER and clonazepam ODT 2 mg, and  $>$  3 units/day of clonazepam ODT 0.125 mg, 0.25 mg, 0.5 mg, and 1 mg.**

1. Can the dose be consolidated within quantity limits?  Yes  No

2. Please describe medical necessity for exceeding the quantity limit.

3. For clonazepam ODT, please indicate prescriber specialty below.

Psychiatry  Neurology  Other \_\_\_\_\_

Specialist consult details (if the prescriber submitting the request is not a specialist)

Name(s) of the specialist(s) \_\_\_\_\_ Date(s) of last visit or consult \_\_\_\_\_

Contact information \_\_\_\_\_

**Section V. Please complete for requests for temazepam 22.5 mg.**

Please attach medical records documenting an inadequate response or adverse reaction to all hypnotic benzodiazepines (e.g., estazolam, flurazepam, temazepam 7.5 mg, 15 mg, or 30 mg, triazolam). Please describe dose consolidation. For requests for > 1 unit/day, describe medical necessity for exceeding the quantity limit.

**Section VI. Please complete for requests for meprobamate.**

1. Has the member had a trial with at least two benzodiazepines?

Yes

Drug name \_\_\_\_\_ Dates \_\_\_\_\_ Outcome \_\_\_\_\_

Drug name \_\_\_\_\_ Dates \_\_\_\_\_ Outcome \_\_\_\_\_

No. Please explain why not. \_\_\_\_\_

2. If requesting recertification, please provide clinical rationale for continued therapy and details of trials with alternatives (e.g., SSRIs, SNRIs, TCAs, buspirone).

**Section VII. Please complete for requests for Byfavo.**

1. Will Byfavo be used for induction and maintenance of procedural sedation?

Yes. Please provide procedure date. \_\_\_\_\_

No.

2. Please provide clinical rationale for use instead of intravenous midazolam.

**Section VIII. Please complete for requests for amitriptyline/chlordiazepoxide.**

Please describe the medical necessity for use of the combination product instead of the commercially available separate agents. \_\_\_\_\_

**Section IX. Please complete for requests for clorazepate and oxazepam.**

Has the member had a trial with two of the following benzodiazepines: alprazolam, chlordiazepoxide, clonazepam, diazepam, or lorazepam?

Yes. Please list the drug names, dates/duration of use, and outcomes below.\*

Drug name \_\_\_\_\_ Dates/duration of use \_\_\_\_\_

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name \_\_\_\_\_ Dates/duration of use \_\_\_\_\_

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

No. Please explain why not. \_\_\_\_\_

*\*Attach a letter with additional information regarding medication trials as applicable.*

---

**Section X. Please complete for requests for Loreev XR.**

Please attach medical records documenting stability with lorazepam tablets in three evenly divided daily doses and trials with two intermediate/long- or long-acting benzodiazepines. If all other long-acting benzodiazepines are contraindicated, please describe. For requests for > 1 unit/day, describe medical necessity for exceeding the quantity limit.

---

**MassHealth Pediatric Behavioral Health Medication Initiative**

**Please fill out all the sections below, as applicable, for pediatric members only. You may also use the Pediatric Behavioral Health Medication Initiative PA Request Form if the member is prescribed other behavioral health medications.**

---

**Section I. Please complete for all requests for medications subject to the Pediatric Behavioral Health Medication Initiative for members < 18 years of age.**

Is the member currently in an acute care setting?

Yes (Inpatient)  Yes (Community Based Acute Treatment)

Yes (Partial Hospitalization)  No

For members who are in an acute care setting, please document the outpatient prescriber after discharge.

Prescriber name \_\_\_\_\_ Contact information \_\_\_\_\_

Has the member been hospitalized for a psychiatric condition within the past three months?

Yes. Please document dates of hospitalization within the past three months. \_\_\_\_\_

No

On the current regimen, is the member considered to be a risk of harm to self or others?

Yes. Please provide details. \_\_\_\_\_

No

For regimens including an antipsychotic, are appropriate safety screenings and monitoring being conducted (e.g. weight, metabolic, movement disorder, cardiovascular, and prolactin-related effects)?

Yes  No. Please explain. \_\_\_\_\_

Has informed consent from a parent or legal guardian been obtained?  Yes  No

Please indicate prescriber specialty below.

Psychiatry  Neurology  Other \_\_\_\_\_

Specialist consult details (if the prescriber submitting the request is not a specialist)

Name(s) of the specialist(s) \_\_\_\_\_ Date(s) of last visit or consult \_\_\_\_\_

Contact information \_\_\_\_\_

For mid-level practitioners (e.g., nurse practitioners, physician assistants), please provide the name and specialty of the collaborating physician, if applicable. \_\_\_\_\_

Please document member custody status.

Parent/Guardian  Department of Children and Families (DCF)

Please document member placement status.

Home with Parent/Guardian  Foster Care  Residential Treatment Facility

Uncertain  Other \_\_\_\_\_

Please document agency involvement.

- Department of Children and Families (DCF)     Department of Mental Health (DMH)
- Department of Developmental Services (DDS)     Department of Youth Services (DYS)

Is the member/family currently receiving appropriate psychotherapeutic and/or community based services for the targeted clinical mental health related concerns (e.g., Applied Behavioral Analysis, Children’s Behavioral Health Initiative, school interventions, specialized placement)?

Yes. Please document details of interventions, if applicable.

No

Psychiatric care provided is coordinated with other psychotherapeutic and community based services.  Yes  No

\* Sample informed consent form available on the MassHealth PBHMI Information webpage. For additional information go to: <https://www.mass.gov/info-details/pediatric-behavioral-health-medication-initiative-pbhmi-information>

**Section II. Benzodiazepine Polypharmacy. Complete this section for all members < 18 years of age, if request will result in prescription of two or more benzodiazepine agents for ≥ 60 days within a 90-day period (excluding hypnotic benzodiazepine agents, clobazam, nasal and rectal diazepam, nasal midazolam, and injectable formulations).**

Please document complete treatment plan (include all benzodiazepine agents).

1. Benzodiazepine name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
2. Benzodiazepine name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
3. Benzodiazepine name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
4. Other(s) \_\_\_\_\_

Please document if monotherapy trials (include drug name, dates/duration of use, and outcome) with benzodiazepine agents were tried before prescribing polypharmacy with two or more benzodiazepine agents in this member.\* \_\_\_\_\_

Please document the treatment plans for medication regimen simplification (e.g., dose consolidation, frequency reduction) or medical necessity for continuation of a complex medication regimen. \_\_\_\_\_

\*Attach a letter with additional information regarding medication trials as applicable.

**Section III. Benzodiazepine Request for Members < six years of age.**

Please document complete treatment plan (include all benzodiazepine agents with dose/frequency/duration and indication(s) for the requested medication(s)). \_\_\_\_\_

Please document if member has other behavioral health comorbidities (e.g., anxiety, sleep disorder). \_\_\_\_\_

For hypnotic benzodiazepine requests, please document medication trials with melatonin and/or clonidine, if clinically appropriate. Include drug name, dates/duration of use, and outcome.\* \_\_\_\_\_

Please document clinical rationale for the use of a benzodiazepine agent in this member < six years of age. \_\_\_\_\_

\*Attach a letter with additional information regarding medication trials as applicable.

---

**Section IV. Multiple Behavioral Health Medications. Complete this section for all members < 18 years of age if request will result in prescriptions of four or more behavioral health medications within a 45-day period. For a complete list of all behavioral health medications, please refer to the MassHealth Pediatric Behavioral Health Medication Initiative.**

Please document complete treatment plan (include all behavioral health agents and indication(s) for each medication(s)).

1. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
2. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
3. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
4. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
5. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
6. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
7. Other(s) \_\_\_\_\_

Please document monotherapy trials (include drug name, dates/duration of use, and outcome) tried before prescribing a polypharmacy regimen for this member.\*

Please document the treatment plans for medication regimen simplification (e.g., dose consolidation, frequency reduction) or medical necessity for continuation of a complex medication regimen.

---

*\*Attach a letter with additional information regarding medication trials as applicable.*

---

**Prescriber information**

Last name\* \_\_\_\_\_ First name\* \_\_\_\_\_ MI \_\_\_\_\_  
NPI\* \_\_\_\_\_ Individual MH Provider ID \_\_\_\_\_  
DEA No. \_\_\_\_\_ Office Contact Name \_\_\_\_\_  
Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
E-mail address \_\_\_\_\_  
Telephone No.\* \_\_\_\_\_ Fax No.\* \_\_\_\_\_

*\* Required*

---

**Prescribing provider's attestation, signature, and date**

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

**Signature required** \_\_\_\_\_

Printed name of prescribing provider \_\_\_\_\_ Date \_\_\_\_\_